ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0992

Impact of Selective Inhibitors of Nuclear Export on SLE Plasma Cells Is Modulated by the BM Microenvironment

Neha Nandedkar-Kulkarni1, Nida Meednu2, Jennifer Albrecht2, Jennifer Barnas2, Douglas Widman3 and Jennifer Anolik2, 1University of Rochester, Rochester, NY, 2University of Rochester Medical center, Rochester, NY, 3Karyopharm Therapeutics, Newton, MA

Meeting: ACR Convergence 2020

Keywords: Apoptosis, autoimmune diseases, B-Cell Targets, interferon, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 8, 2020

Title: B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Systemic lupus erythematous (SLE) is a complex autoimmune disorder with heterogeneous disease presentation and a multi-pronged pathogenesis. Although autoreactive plasma cells play a key role in SLE, they are still elusive targets. Selective inhibitors of nuclear export (SINE) were recently approved by the FDA for treatment of refractory multiple myeloma (selinexor). Our lab has demonstrated that SINE abrogate lupus nephritis and significantly reduce autoreactive plasma cells in lupus prone NZBW/F1 mice. Here we investigated the impact of SINE on In vitro survival and antibody secretion of human plasma cells (PC) and how these classic PC functions are modulated by the bone marrow (BM) microenvironment.

Methods: Peripheral blood mononuclear cells (PBMCs) and bone marrow mononuclear cells (BMMCs) from healthy (n = 4) and SLE donors (n = 4), cultured in the presence of mesenchymal stromal cell secretome, were treated with KPT-335 for different periods of time. Number of antibody secreting cells (ASC) and PC survival were assessed by IgG ELISPOT and annexin V-propidium iodide flow based apoptosis assay, respectively. CD19+CD27hiCD38hi blood plasmablasts, CD19+CD27hiCD38hiCD138+ BM mature PCs and CD19–CD27hiCD38hiCD138+ BM long-lived PCs were sorted for transcriptomic analysis (controls: n = 7 and SLE: n = 9).

Results: Blood ASC were significantly reduced (IC50= 0.1uM) compared to BM ASC (IC50 = 10uM) after short-term ex vivo treatment with KPT-335 (24 hours). In long-term cultures (120 hours), there was a greater impact on BM PCs (IC50=0.1uM). We also examined the capacity of SINEs to induce apoptosis in different PC subsets. Blood plasmablasts from both healthy and SLE donors were reduced by 30-70% after SINE treatment for 48 hours. Of note, SINE treatment did not affect BM mature and long-lived PC. In transcriptomic analysis, BM PCs showed up-regulation of NFkB signaling and extra-cellular matrix receptor interactions (gene pathway analysis), and experienced down-regulation of cell cycle signaling pathways, compared to blood PC. Mature and long-lived PC in lupus BM had a prominent interferon (IFN) signature compared to controls. We are currently investigating the impact of type I IFN on PC survival and function.

Conclusion: SINEs represent a novel treatment approach for SLE. These results support the hypothesis that the effect of SINEs on PC depends upon the dose and duration of treatment, and is modulated by BM microenvironmental signals that orchestrate PC survival.


Disclosure: N. Nandedkar-Kulkarni, None; N. Meednu, None; J. Albrecht, None; J. Barnas, None; D. Widman, Karyopharm Therapeutics, 3; J. Anolik, None.

To cite this abstract in AMA style:

Nandedkar-Kulkarni N, Meednu N, Albrecht J, Barnas J, Widman D, Anolik J. Impact of Selective Inhibitors of Nuclear Export on SLE Plasma Cells Is Modulated by the BM Microenvironment [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/impact-of-selective-inhibitors-of-nuclear-export-on-sle-plasma-cells-is-modulated-by-the-bm-microenvironment/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/impact-of-selective-inhibitors-of-nuclear-export-on-sle-plasma-cells-is-modulated-by-the-bm-microenvironment/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology